Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FIRST QUARTER OF 2025

Leverkusen (pta014/30.05.2025/13:00 UTC+2)

" Leverkusen - Biofrontera AG (ISIN: DE000A4BGGM7), an international biopharmaceutical company, today published its results for the first three months ended March 31, 2025.

Key financial figures and business performance Q1 2025

"We continue to maintain sustainable growth in Europe, with outstanding development in the German market, where, in addition to increasing our sales by more than 25%, we have achieved a 73% market share in the photodynamic therapy segment, positioning ourselves as the undisputed leader in this field," stated Ms. Pilar de la Huerta Martinez, CFO and Managing Director of the Biofrontera Group.

The return to normal purchase order levels from our U.S. partner Biofrontera Inc. has also led to a significant increase in revenue for this first quarter. The increase in revenue, together with the significant reduction in expenses—driven, among other factors, by the transfer of clinical trial programs to Biofrontera Inc.—has led to a substantial improvement in the company's results for this first quarter. However, the financial difficulties currently faced by Biofrontera Inc., the payment deferrals, and the ongoing negotiations between the two companies prevent us from predicting how the relationship will ultimately evolve and what impact it will have on Biofrontera AG." mentioned Ms. de la Huerta Martinez.

At EUR 5,768 thousand, the company's revenue for the period from January 1 to March 31, 2025 was 55% above the previous year's figure of EUR 3,713 thousand.

In the USA, the company generated revenue of EUR 2,462 thousand in the first quarter compared to EUR 327 thousand in the same period of the previous year, as Biofrontera Inc has returned to the normal level of purchase orders, stopped during 2024 due to their change in the stockpiling policy.

In Germany, product sales of EUR 2,462 thousand were achieved in the first quarter, an increase of 26,5% compared to the first quarter of the previous year (EUR 1,946 thousand). In Spain and UK, the sales are in line with last year, although revenues with related partners in EU went down from EUR 739 thousand in Q1 2024 to EUR 159 thousand. This pattern, in which distributors place large purchase orders in alternating years, is completely normal, with 2025 being a year of reduced purchases.

Gross profit was also higher than last year. This, jointly with a lower level of expenses, mainly in the R&D area, drives the company to a positive EBIT, of EUR 803 compared with EUR -1,555 thousand

The Group's cash and cash equivalents totaled EUR 4,897 thousand as of March 31, 2025 compared to EUR 3,124 thousand as of December 31, 2024. From today's perspective, Biofrontera AG has sufficient liquidity to implement the Group strategy over the next 12 months if Biofrontera Inc fulfills its binding obligations in terms of purchase orders and payments and the rest performs as planned.

Guidance

The company recalls the outlook published in April 2025, Given the current liquidity constraints faced by Biofrontera Inc. and the material impact this customer has on our consolidated revenue base, Management is currently unable to reliably assess the potential implications on our sales and earnings guidance. Once Biofrontera AG's Management has greater visibility into the financial outlook of Biofrontera Inc. and its ability to fulfill its contractual obligations, a revised outlook will be issued to reflect the updated risk profile and operational scenario."

(end)

Emitter:	Biofrontera AG Hemmelrather Weg 201 51377 Leverkusen Germany
Contact Person:	Investor Relations
Phone:	+49 (0) 214 87 63 20
E-Mail:	ir@biofrontera.com
Website:	www.biofrontera.com
ISIN(s):	DE000A4BGGM7 (Share)
Stock Exchange(s):	Regulated Market in Dusseldorf, Frankfurt; Free Market in Berlin, Munich, Stuttgart, Tradegate